Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD study of RTX001 autologous macrophages in decompensated liver cirrhosis
2024-516288-10-00Phase 2Authorised
- Sponsor
- Resolution Therapeutics
- Start
- Mar 2025
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of RTX001 in Cirrhosis, sponsored by Resolution Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Changes from baseline in safety assessments and 1 more. Planned start Mar 2025; status: authorised.
02
Drugs
RTX001
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2024-516288-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516288-10-00.